News | December 29, 2014

Jury Still Out on Effectiveness of PET/MRI Versus PET/CT

Clinical trial results are inconclusive to date while costs of PET/MRI are debated

December 29, 2014 — Manufacturers have introduced hybrid imaging systems that combine positron emission tomography (PET) with magnetic resonance imaging (MRI). The purported benefit is improved detail in organ and soft-tissue images without the ionizing radiation inherent with systems that combine PET with computed tomography (CT), the gold-standard hybrid imaging modality.

Utilization is affected by the uncertain reimbursement environment for integrated PET/MRI scans. Some private, third-party payers (Aetna, Anthem, Humana) deny coverage for the hybrid imaging exams. Clinical trials comparing PET/MRI to PET/CT imaging have generally not demonstrated a substantial difference in diagnostic accuracy between PET/MRI and PET/CT, affecting anticipated utilization.

ECRI Institute’s expert panel thought that the possible development of new PET radiotracers targeting brain structures and soft tissue tumors might increase PET/MRI utilization for certain indications, especially if evidence demonstrates a benefit in diagnostic accuracy and if reimbursement becomes available.

Potential Health Impact
Most clinical trials of PET/MRI underway are comparing it with PET/CT. Heusch et al. (2014) found no significant differences in tumor detection between the two modalities. Quick et al. (2013) reported that PET/MRI detected more tumors than PET/CT. However, other trials (Chandarana et al. 2013, Gaertner et al. 2013, Wiesmuller et al. 2013) found that PET/MRI detected most tumors identified by PET/CT. Afshar-Oromieh et al. (2014) and Beiderwellen et al. (2013) concluded that PET/MRI may have better contrast and tumor conspicuity than PET/CT, but Gaertner et al. (2013) found better tumor conspicuity with PET/CT.

Potential Financial Impact
Hospitals face substantial costs to acquire integrated PET/MRI technology, including construction or renovation required to accommodate the combined system’s physical requirements and to install MRI-compatible (nonmagnetic) ancillary medical equipment needed during imaging procedures. As changes in healthcare coverage place a greater financial burden on healthcare consumers, some patients may forgo expensive procedures or diagnostic tests, thereby reducing demand for some technologies.

For more information: www.ecri.org

Related Content

Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Overlay Init